Exchange Delays Conclusion of Delisting Review for Kolon TissueGene

Kolon Life Science Headquarters, Gangseo-gu, Seoul

[Asia Economy Reporter Choi Dae-yeol] The Korea Exchange has decided to resume deliberations regarding the delisting of Kolon TissueGene, a KOSDAQ-listed company.

On the 7th, the KOSDAQ Market Headquarters of the Exchange announced, "As a result of holding the KOSDAQ Market Committee, it was decided to continue the deliberations." Previously, Kolon TissueGene was subject to a substantive review of listing eligibility due to controversy over the components of the new drug 'Invossa-K' (Invossa), and its stock trading has been suspended for nearly three years since May 2019.

The KOSDAQ Market Committee granted improvement periods twice in 2019 and 2020, which ended in December last year, and the company submitted the final improvement plan implementation report last month. The KOSDAQ Market Headquarters stated, "Separately, after the improvement period granted by the Corporate Evaluation Committee ends at the end of August, a review and resolution will be conducted to decide on the delisting."